Trevi Therapeutics Inc
TRVI12.100USD
+0.430+3.68%
收盤 11/11, 16:00（美東）報價延遲15分鐘
1.47B總市值
虧損本益比TTM
關於 Trevi Therapeutics Inc 公司
Trevi Therapeutics, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於開發和商業化試驗性療法 Haduvio（納布啡 ER），用於治療患有特發性肺纖維化 (IPF) 和其他慢性咳嗽適應症的成人慢性咳嗽，以及治療結節性癢疹。Haduvio 是納布啡的口服緩釋 (ER) 製劑。納布啡是一種混合的 k-阿片受體激動劑和 mu-阿片受體拮抗劑。該公司正在對患有與結節性癢疹相關的嚴重瘙癢症的患者進行 Hadguvio 的 IIb/III 期臨牀試驗。該公司還對 IPF 患者的慢性咳嗽進行了 Haduvio 的 II 期臨牀試驗，該試驗稱爲 II 期 CANAL 試驗。該公司的 Haduvio 開發計劃包括 IPF 慢性咳嗽計劃、RCC 計劃和結節性癢疹計劃。該公司的子公司是 Trevi Therapeutics Limited。
Trevi Therapeutics Inc簡介
公司代碼TRVI
公司名稱Trevi Therapeutics Inc
上市日期May 07, 2019
CEOMs. Jennifer L. Good
員工數量26
證券類型Ordinary Share
年結日May 07
公司地址195 Church St Fl 14
城市NEW HAVEN
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編06510-2009
電話12033042499
網址https://www.trevitherapeutics.com/
公司代碼TRVI
上市日期May 07, 2019
CEOMs. Jennifer L. Good
Trevi Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. David P. Meeker, M.D.
Dr. David P. Meeker, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
352.49K
--
Dr. Thomas R. Sciascia, M.D.
Dr. Thomas R. Sciascia, M.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
214.43K
--
Ms. Jennifer L. Good
Ms. Jennifer L. Good
President, Chief Executive Officer, Interim Chief Financial Officer, Director
President, Chief Executive Officer, Interim Chief Financial Officer, Director
213.31K
--
Dr. Farrell Simon, Pharm.D.
Dr. Farrell Simon, Pharm.D.
Chief Commercial Officer
Chief Commercial Officer
76.90K
+68.46%
Ms. Anne M. Vanlent
Ms. Anne M. Vanlent
Independent Director
Independent Director
25.98K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Independent Director
Independent Director
6.35K
--
Dr. James V. (Jim) Cassella, Ph.D.
Dr. James V. (Jim) Cassella, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Dominick C. Colangelo
Mr. Dominick C. Colangelo
Independent Director
Independent Director
--
--
Mr. Edward T. Mathers
Mr. Edward T. Mathers
Independent Director
Independent Director
--
--
Jonathan Carlson
Jonathan Carlson
IR Contact Officer
IR Contact Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. David P. Meeker, M.D.
Dr. David P. Meeker, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
352.49K
--
Dr. Thomas R. Sciascia, M.D.
Dr. Thomas R. Sciascia, M.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
214.43K
--
Ms. Jennifer L. Good
Ms. Jennifer L. Good
President, Chief Executive Officer, Interim Chief Financial Officer, Director
President, Chief Executive Officer, Interim Chief Financial Officer, Director
213.31K
--
Dr. Farrell Simon, Pharm.D.
Dr. Farrell Simon, Pharm.D.
Chief Commercial Officer
Chief Commercial Officer
76.90K
+68.46%
Ms. Anne M. Vanlent
Ms. Anne M. Vanlent
Independent Director
Independent Director
25.98K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Independent Director
Independent Director
6.35K
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
New Enterprise Associates (NEA)
9.34%
Frazier Life Sciences Management, L.P.
8.42%
Rubric Capital Management LP
7.01%
The Vanguard Group, Inc.
4.77%
BlackRock Institutional Trust Company, N.A.
4.64%
其他
65.82%
持股股東
持股股東
佔比
New Enterprise Associates (NEA)
9.34%
Frazier Life Sciences Management, L.P.
8.42%
Rubric Capital Management LP
7.01%
The Vanguard Group, Inc.
4.77%
BlackRock Institutional Trust Company, N.A.
4.64%
其他
65.82%
股東類型
持股股東
佔比
Hedge Fund
25.75%
Investment Advisor
23.38%
Investment Advisor/Hedge Fund
17.39%
Venture Capital
14.71%
Private Equity
11.14%
Research Firm
2.32%
Individual Investor
0.80%
Pension Fund
0.35%
Bank and Trust
0.12%
其他
4.03%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
272
116.14M
95.37%
+14.43M
2025Q2
232
94.28M
77.42%
+5.93M
2025Q1
226
89.66M
76.74%
+2.50M
2024Q4
177
80.67M
91.74%
+11.34M
2024Q3
156
59.14M
78.18%
-6.31M
2024Q2
148
56.93M
80.80%
-4.85M
2024Q1
147
52.57M
76.38%
-8.69M
2023Q4
131
54.54M
85.48%
-544.63K
2023Q3
124
54.64M
88.55%
-1.52M
2023Q2
115
54.75M
93.54%
+3.66M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
New Enterprise Associates (NEA)
11.37M
9.34%
-1.85M
-14.01%
Aug 11, 2025
Frazier Life Sciences Management, L.P.
10.26M
8.42%
--
--
Jun 30, 2025
Rubric Capital Management LP
8.53M
7.01%
+3.99M
+87.99%
Jun 30, 2025
The Vanguard Group, Inc.
5.32M
4.37%
+1.48M
+38.53%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.65M
4.64%
+1.10M
+24.11%
Jun 30, 2025
Vivo Capital, LLC
4.49M
3.69%
+1.00M
+28.67%
Jun 30, 2025
AllianceBernstein L.P.
4.28M
3.52%
+4.26M
+19064.53%
Jun 30, 2025
Woodline Partners LP
4.05M
3.32%
+1.99M
+96.64%
Jun 30, 2025
Invus Public Equities Advisors, LLC
3.94M
3.23%
+1.07M
+37.54%
Jun 30, 2025
Octagon Capital Advisors LP
3.67M
3.02%
+350.00K
+10.54%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
SPDR S&P Pharmaceuticals ETF
1.38%
Invesco Dorsey Wright Healthcare Momentum ETF
1.1%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.03%
ALPS Medical Breakthroughs ETF
0.66%
Invesco Dorsey Wright SmallCap Momentum ETF
0.42%
Optimize Strategy Index ETF
0.29%
Vanguard US Momentum Factor ETF
0.21%
iShares Micro-Cap ETF
0.15%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.11%
查看更多
SPDR S&P Pharmaceuticals ETF
佔比1.38%
Invesco Dorsey Wright Healthcare Momentum ETF
佔比1.1%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比1.03%
ALPS Medical Breakthroughs ETF
佔比0.66%
Invesco Dorsey Wright SmallCap Momentum ETF
佔比0.42%
Optimize Strategy Index ETF
佔比0.29%
Vanguard US Momentum Factor ETF
佔比0.21%
iShares Micro-Cap ETF
佔比0.15%
ProShares Ultra Nasdaq Biotechnology
佔比0.12%
Invesco Nasdaq Biotechnology ETF
佔比0.11%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
